Company / Return on Assets (ROA)
Allogene Therapeutics, Inc. Return on Assets (ROA) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-45.9%
FY2025
5-year range
-59.6% / -16.3%
FY2021-FY2025
Trend
+23.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) returned to growth in FY2025 after 2 years of decline, reaching -45.9%.
Based on SEC 10-K filings.
-45.9% in FY2025 with a 3-year CAGR of -29.6%.
Declined from -28.3% to -45.9% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -29.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 23.0% year-over-year.
- Peak return on assets (roa) was recorded in FY2022.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -45.9% | +23.0% |
| FY2024 | -59.6% | -110.6% |
| FY2023 | -28.3% | -74.3% |
| FY2022 | -16.3% | +8.6% |
| FY2021 | -17.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026